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Following allogeneic haematopoietic stem cell transplantation
(HSCT), adherence to immunosuppressants (IS) is crucial to
prevent and treat chronic GvHD (cGvHD), which is associated
with reduced quality of life, increased morbidity and mortality,
and increased overall health-care needs.1 According to Vrijens’2
taxonomy of medication nonadherence (MNA), it can be deﬁned
as a deviation from the prescribed medication regimen sufﬁcient
to adversely inﬂuence the regimen’s intended effect. This may
involve late or non-initiation of the prescribed treatment,
suboptimal implementation of the dosing regimen (taking; drug
holidays; timing; dose reduction), early discontinuation of
treatment or any combination of these.2 Although studies in the
HSCT population are lacking, evidence in oral anti-tumour CML
treatment shows alarming prevalences of up to 85.8%.3,4
Identifying patients at risk of MNA and developing adherence-
enhancing interventions for them demands an understanding of
the underlying reasons for nonadherence. Therefore, the aims
of this study were: (1) to describe the prevalence of different
forms of MNA, (2) to examine associations between MNA and
selected correlates and (3) to explore the association between
immunosuppressive MNA and cGvHD.
This report is a secondary data analysis of the multicentre
cross-sectional PROVIVO study investigating patient-reported
outcomes of long-term survivors after allo-HSCT (NCT01275534).5
Convenience sampling was used to recruit allogeneic HSCT
recipients from the University Hospitals of Basel and Zurich
between November 2011 and November 2012. Detailed
descriptions of the PROVIVO researchers’ data collection proce-
dures are described elsewhere.5
In accordance with Vrijens’2 taxonomy, the six-item ‘Basel
Assessment of Adherence to Immunosuppressive Medication
Scale (BAASIS)’6 was used to measure patients’ self-reported IS
medication adherence on different dimensions (for example,
initiation, implementation—taking, dose reduction, timing, drug
holiday—discontinuation) over the preceding 4 weeks.2 Patients’
medication adherence was also assessed by a senior physician
from each of the two centres. On the basis of IS blood tests, a
personal review of patients’ medication intake behaviour, the
senior physician noted whether a subject seemed to have been
fully adherent (YES = adherent / NO=nonadherent).6
On the basis of these measures a composite MNA adherence
score was created for each patient. Patients were classiﬁed as
nonadherent if they reported nonadherence on at least one of the
six BAASIS items (for example, taking, timing and so on) and/or
were identiﬁed as nonadherent by the physician assessment.
Clinical and demographic variables were retrieved from patients
charts and the transplant database. In order to describe the
prevalences of the different dimensions of MNA we used
descriptive statistics. Second, a univariate binary logistic regression
was applied in order to examine associations between MNA and
selected clinical correlates. A full record of variables is shown in
Table 2. The clinical variables were selected based on the
author’s literature review on possible risk factors for MNA in
haematology. Factors arising from the univariate analysis that
revealed signiﬁcant P-values (o0.05) were entered in an additional
multivariate binary logistic regression model. For our third aim
we used multivariate binary logistic regression to explore the
association between immunosuppressive MNA and cGvHD.
Of 638 eligible HSCT recipients in follow-up care, 376 (58.9%)
participated. Of these, 99 (26.3%) were taking IS medications and
were, therefore, included. Table 1 presents demographic and
clinical characteristics of patients both in total and grouped by
adherence/nonadherence.
The prevalence of MNA along the different dimensions of
medication taking was the following: 64 patients (64.6%) showed
some kind of nonadherence, of these, 33.3% of patients had
missed at least one IS dose in the past 4 weeks. Three patients
(3.2%) reported drug holidays, that is, missing at least two
consecutive doses. Timing nonadherence occurred in 61.2% of
cases, meaning that they took their medications more than 2 h
early or too late. Four patients (4.1%) reduced their medication
doses on their own and three patients (3.1%) discontinued their
medication intake without asking their physician.
Physicians reported nonadherence in 18 patients (18.9%).
Combining patients’ self-reported MNA with physicians’
assessments yielded a nonadherence prevalence of 68.7% across
the entire sample, 62.2% in patients with no/mild cGvHD and
80.2% in patients with moderate/severe cGvHD. Binary regression
analysis correlated MNA signiﬁcantly with higher numbers of daily
taken IS pills (odds ratio (OR): 1.42; 95% conﬁdence interval
(CI): 1.08–1.87; P= 0.011) and with immunosuppressive therapies
using either calcineurin inhibitor alone or calcineurin inhibitor
steroid combinations, as well as with a lower number of daily
prescribed concomitant medications (OR: 0.85; CI: 0.74–0.98;
P= 0.024). Ordinal logistic regression showed a positive
association between MNA and higher grades of cGvHD (OR:
3.01; CI: 1.27–7.14; P= 0.012), Table 2.
This is the ﬁrst study to describe an association between cGvHD
and MNA. A high prevalence of MNA was shown, particularly
regarding timing and taking. Surprisingly, not only patients taking
higher numbers of IS agents, but also those taking lower numbers
of concomitant medications were more likely to be nonadherent.
Current evidence regarding solid organ transplant patients
indicates clear associations between small deviations from
prescribed immunosuppressive medication schedules and poor
clinical outcomes6 (for example, deviations 45% from dosing
schedules has been associated with increased incidences of graft
loss or late acute rejection in renal and heart transplant recipients).
However, no information is available on a deviation threshold for
diminished outcomes in HSCT. Therefore, further prospective
research is needed to develop a clinically meaningful deﬁnition of
IS MNA, and to explore possible causal relationships between
dosing schedule deviations and poor clinical outcomes in the
HSCT population.
Importantly, this study adds MNA as a behavioural pathway to
the genetic and biophysiological components of cGvHD
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pathophysiology. Given the expected growth of GvHD patient
numbers (resulting from the increased use of mobilised peripheral
blood HSCT, reduced conditioning regimens, broader indications
for mismatched/unrelated donors and older HSCT recipients)
further understanding of this risk factor is crucial.
Also, the heterogeneous nature of the disease is only partially
understood: the absence of evidence-based second- and third-line
management options poses further challenges.7–9
So far, only a few clinical trials have integrated medication
taking measurements in their study designs. Determining
what part of GvHD outcome variability is due to issues in
immunosuppressive taking behaviours will call for the inclusion of
medication adherence as a vital parameter in HSCT research.
Our study identiﬁed two therapy-related factors associated with
MNA: ‘number of daily taken IS pills’ (positive correlation)
and ‘number of daily taken concomitant medications’
(inverse correlation).
Although barriers to regular IS intake might include the
unpleasant smell and taste of pills or cGvHD involvement of
the mouth, one possible explanation for the inverse correlation
between numbers of concomitant medications and MNA might be
Table 1. Demographic and clinical characteristics (N= 99)
Characteristics Total
N= 99
Nonadherenta
n= 65
Adherent
n= 34
Age, median 51.0 51.0 53.0
(IQR; range) (18.7;
20.3–71.8)
(19.4;
20.8–71.8)
(15.6;
20.3–68.1)
Years after HSCT, median 3.9 4.0 3.9
(IQR; range) (5.0;
1.0–29.0)
(4.7; 1.0–29.0) (5.9;
1.0–26.0)
Gender; male, n (%) 61 (61.6) 42 (64.6) 19 (55.9)
Marital status, n (%)
Married or cohabited 75 (75.8) 49 (75.4) 26 (76.5)
Haematological diagnosis, n (%)
Acute leukaemia (AML, ALL) 49 (49.5) 33 (50.8) 16 (47.1)
CML / MDS / MPS 22 (22.2) 14 (21.5) 8 (23.5)
Lymphoma / CLL / MM 27 (27.2) 17 (26.2) 10 (29.4)
Non-malignant haematologic
disease
1 (1.0) 1 (1.5) 0 (0.0)
Status of haematological disease, n (%)
CR 92 (92.9) 63 (96.9) 29 (85.3)
Myeloablative treatment regimen
(conditioning), n (%)
75 (76.5) 52 (81.3) 23 (67.6)
TBIb, n (%)
Yes 65 (66.3) 44 (68.8) 21 (61.8)
Donor relationship, n (%)
Unrelated 52 (52.5) 35 (53.8) 17 (50.0)
Identical sibling or matched
related
44 (44.4) 29 (44.6) 15 (44.1)
Mismatched related 3 (3.0) 1 (1.5) 2 (5.9)
cGvHDc, n (%)
No 22 (22.7) 10 (15.6) 12 (36.4)
Yes 75 (77.3) 54 (84.4) 21 (63.6)
Not documentedd 2 (2.0) 1 (1.5) 1 (2.9)
cGvHD grade in cases (n = 75) according to NIH criteria
Mild 39 (52.0) 26 (48.1) 13 (62.0)
Moderate 27 (36.0) 20 (37.0) 7 (33.3)
Severe 9 (12.0) 8 (14.8) 1 (4.8)
Functional impairmente, n (%)
80–100% 80 (82.5) 55 (87.4) 25 (73.5)
o80% 17 (17.5) 8 (12.7) 9 (26.5)
Not documented 2 (2.0) 2 (3.1) 0 (0.0)
Immunosuppressive regimen, n (%)
Steroidsf only 11 (11.6) 3 (4.8) 8 (25.0)
CNI (CYA or tacrolimus) only 48 (50.5) 33 (52.4) 15 (46.9)
Others (mTOR inhibitor or
mycophenolate)
5 (5.3) 3 (4.8) 2 (6.3)
Combination (+ steroidse) 31 (32.6) 24 (38.1) 7 (21.9)
Not documented 4 (4.0) 2 (3.1) 2 (5.9)
Number of IS pills, median 2.5 3.0 2.0
(IQR; range) (2–4.25;
1–12)
(2.0–5.0;
1–10)
(1.25–3.75;
1–12)
Number of concomitant medications,
median
8.0 8.0 9.0
(IQR; range) (5.0–10.0;
1–22)
(5.0–10.0;
1–14)
(6.0–11.0;
1–22)
Abbreviations: cGvHD= chronic GvHD; CNI= calcineurin inhibitor;
CYA= cyclosporine A; HSCT=haematopoietic stem cell transplantation;
IQR= interquartile range; IS= immunosuppressants; MDS=myelodysplas-
tic syndrome; MM=multiple myeloma; MPS=myeloproliferative syn-
drome; mTOR=mammalian target of rapamycin; NIH=National Institutes
of Health. aNonadherence is any YES answer on any of the ﬁve items of the
BAASIS. bPrevalence of patients who had a TBI in the conditioning regime
with 12 Gray. ccGvHD was rated by the physician with the cGvHD grading
scheme recommended by the National Institutes of Health consensus
development project on criteria for clinical trials in cGvHD. dNot reported
are missing data and show valid percentages. eFunctional impairment
using the Karnofsky Performance Status was determined by the physician
at the annual follow-up visit and comprises a scoring of individual’s health
and physical functionality based on criteria-related performance index
rated from 100% (normal function) to 10% (moribund). fPrednisone with a
dosage of at least 2.5 mg per day.
Table 2. Correlates of composite MNA in univariate and multivariate
analyses
Adjusted model for transplant
centre
OR (95% CI) df P-value
Univariate binary logistic regressiona (N= 99)
Age 0.985 (0.952–1.019) 1 0.373
Gender 0.533 (0.220–1.289) 1 0.162
Years after HSCT 0.984 (0.903–1.073) 1 0.714
Number of daily taken IS pills 1.328 (1.042–1.694) 1 0.022
Immunosuppressive regimen 3 0.067
CNI (CYA or tacrolimus) onlyb 5.513 (1.175–25.857) 1 0.030
Others (mTOR inhibitor or
mycophenolate)b
2.650 (0.253–27.781) 1 0.416
Combination (+ steroids)c 8.560 (1.623–45.159) 1 0.011
Number of daily taken
concomitant medications
0.871 (0.766–0.990) 1 0.035
Functional impairmentd 1.016 (0.987–1.047) 1 0.282
Depressive symptomatology 0.860 (0.271–2.733) 1 0.798
Nausea 0.801 (0.519–1.235) 1 0.314
Multivariate binary logistic regressiona (N= 99)
Higher number of IS pills is
associated with MNA
1.422 (1.083–1.867) 1 0.011
Lower number of concomitant
medications is associated with
MNA
0.852 (0.742–0.979) 1 0.024
Transplant centre is associated
with MNA
0.174 (0.055–0.553) 1 0.003
The explained variance of the adjusted model is acceptable
(Nagelkerke R2: 22.7%).
Abbreviations: CI= conﬁdence interval; CNI= calcineurin inhibitor;
CYA= cyclosporine A; df=degrees of freedom; HSCT=haematopoietic
stem cell transplantation; IS= immunosuppressants; MNA=medication
nonadherence; mTOR=mammalian target of rapamycin; OR= odds ratio;
WHO=World Health Organization. aOutcome variable for the regression
analyses were the composite MNA adherence score. For the univariate
binary logistic regression, correlates were selected based on the WHO
adherence model and evidence of the literature regarding risk factors for
MNA in haematology.3,4 bReference category: steroids. cPrednisone with a
dosage of at least 2.5 mg. dFunctional impairment using the Karnofsky
Performance Status was determined by the physician at the annual follow-
up visit and comprises an individual’s health and physical functionality
based on a criteria-related performance index rated from 100% (normal
function) to 10% (moribund).
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that patients with fewer concomitant medications pay less
attention to their medication management. Research in solid
organ transplantation10 indicates that barriers to adherence are
often unintentional (for example, forgetfulness/interruption of
daily routine) or determined by patients’ attitudes (for example,
the belief that not all IS are necessary to prevent rejection).11
Clinicians recognise that patients consciously or unconsciously
reduce or omit IS intake, potentially leading to cGvHD
exacerbation. Clinical experience shows that some patients with
treatment refractory disease eventually lose their belief in their
medications’ effectiveness (‘the drugs don’t work’).12
However, whatever the reasons behind MNA, supporting
patients’ medication management is a key task for transplant
teams. Throughout the long-term process of post-treatment
follow-up, multidisciplinary teams collaborate to improve
patients’ HSCT outcomes. For example, a nurse-coordinated
intervention programme, integrated within systems of care, could
offer an opportunity to assess medication-taking behaviours and
initiate individually tailored adherence-enhancing interventions
with components proven to be effective against MNA, for
example, brief (maximum one page) written medication
adherence instructions, electronic reminders to take medications
regularly, assistance with dose modiﬁcations, coaching for
self-monitoring and side effect management.
Also, as developing and initiating state-of-the-art adherence
interventions will demand an appropriately skilled clinical work
force, it will be essential to integrate medication adherence-
related topics into health-care providers’ on-going education and
training, and to support and evaluate innovative care approaches.
The ﬁndings of this secondary analysis must be interpreted in
the context of potential limitations. The small sample size of this
cross-sectional study allows only a small set of study variables and
limits the statistical power. Concerning measurement accuracy,
although combining self-report questionnaires with physicians’
collateral reports results in greater sensitivity than either alone,
the additional use of electronic monitoring would have provided
the greatest possible sensitivity in detecting MNA.13
To conclude, our study demonstrated a high prevalence of MNA
in the studied HSCT population, and established, for the ﬁrst time,
a positive association between MNA and cGvHD. Our ﬁndings call
for future research of the behavioural dimension of cGvHD
management, including the development and testing of a set of
adherence-enhancing interventions, for routine application at
HSCT centres.
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